A Phase 3 interventional study of Olaparib and 5-FU in Metastatic Colorectal Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 129 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 31st largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2020, is one of 42 in phase 3, and was the 168th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Gilead Sciences · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Oncolytics Biotech · Sites in United States
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 150 · Phase 3 48 · Phase 4 8
First in 2000; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 335 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 224 interventional studies. Of the 144 that completed or were terminated, 50 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 230 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
25 studies in Colorectal Neoplasms by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 21 finished, 19 (90%) have results posted.
Among the 25 studies in Colorectal Neoplasms by Merck & Co., Inc, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 19th registered.
Merck & Co., Inc’s Colorectal Neoplasms studies by the year they started, since 2004.
14 of the studies testing bevacizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT07007728Peking University Cancer Hospital & InstituteIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | 2026-12-31 |
| NCT03401294University of SaskatchewanConversion From Unresectable To Resectable Metastatic Colorectal Cancer. | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 25 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. The primary hypotheses are: Olaparib + Bevacizumab is superior to a fluoropyrimidine + Bevacizumab with respect to progression-free survival (PFS) using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR); Olaparib is superior to a fluoropyrimidine + Bevacizumab with respect to PFS using RECIST 1.1 as assessed by BICR. As of amendment 5 study enrollment is being discontinued and study participants randomized to one of the two experimental arms (olaparib plus bevacizumab or olaparib monotherapy) must discontinue study intervention. Participants who are still on study treatment will no longer have tumor response assessments by BICR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has not progressed (ie, achieved a stable disease [SD], partial response [PR], or complete response [CR]) after a induction course of at least 6 cycles of folinic acid/fluorouracil/oxaliplatin (FOLFOX) + bevacizumab or 4 cycles of capecitabine and oxaliplatin (CAPOX) + bevacizumab as first-line therapy.
Has experienced unacceptable toxicity to oxaliplatin that, in the opinion of the treating physician, requires/required the discontinuation of oxaliplatin. Note: As an example, unacceptable toxicity may include (but is not limited to) severe or prolonged neurotoxicity.
Exclusion Criteria:
Has 1 or more conditions that, in the opinion of the treating physician, make the participant ineligible for treatment with bevacizumab. These conditions may include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive olaparib (300 mg twice daily \[BID\] oral) + Bevacizumab (5 mg/kg intravenous \[IV\] once every 2 weeks \[Q2W\]) until progressive disease or end of study.
Drug: Olaparib · Drug: Bevacizumab
Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.
Drug: Olaparib
Participants will receive investigator's choice of either bevacizumab (7.5 mg/kg IV once every three weeks (Q3W)) + capecitabine (1000 mg/m\^2 BID for 14 days, then 7 days off, Q3W) or bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5-FU (400 mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion). Leucovorin or levoleucovorin 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion. Treatment will continue until progressive disease or end of study.
Drug: 5-FU · Drug: Bevacizumab · Drug: Capecitabine · Drug: Leucovorin/ levoleucovorin
300 mg BID, oral until progressive disease or end of study
Also known as: LYNPARZA^TM
2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
Also known as: Fluorouracil, Adrucil, Efudex
5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
Also known as: MVASI^TM, Avastin
1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
Also known as: XELODA^®
Drug pages: Leucovorin · Levoleucovorin
400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
Also known as: Folinic Acid, Fusilev^®, Khapzory^TM
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS using RECIST 1.1 as assessed by BICR is presented.
Time frame: Up to approximately 30 months
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause. The OS is presented.
Time frame: Up to approximately 30 months
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Time frame: Up to approximately 30 months
Number of Participants With One or More Adverse Events (AE)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE was reported for each arm.
Time frame: Up to approximately 30 months
Number of Participants Discontinuing Study Intervention Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE was reported for each arm.
Time frame: Up to approximately 30 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. DOR is defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis will be censored at the date of their last tumor assessment. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions is also considered PD. DOR assessments will be based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experience a confirmed CR or PR will be presented.
Time frame: Up to approximately 30 months
| Milestone | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Started | 111 | 115 | 109 |
| Treated | 111 | 113 | 108 |
| Completed | 0 | 0 | 0 |
| Not completed | 111 | 115 | 109 |
| Withdrew: Death | 48 | 50 | 52 |
| Withdrew: Physician decision | 0 | 0 | 2 |
| Withdrew: Sponsor decision | 55 | 61 | 50 |
| Withdrew: Withdrawal by subject | 8 | 4 | 5 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS using RECIST 1.1 as assessed by BICR is presented.
| Months | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) | 3.7 (3.4 to 5.3) | 3.6 (2.0 to 3.7) | 5.5 (3.8 to 5.6) |
OS was defined as the time from randomization to death due to any cause. The OS is presented.
| Months | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Overall Survival (OS) | 21.2 (15.1 to NA) | 21.6 (17.2 to NA) | 19.9 (13.8 to 22.5) |
ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
| Percentage of Participants | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR | 4.8 (1.6 to 10.9) | 1.9 (0.2 to 6.6) | 4.8 (1.6 to 10.8) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE was reported for each arm.
| Participants | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Number of Participants With One or More Adverse Events (AE) | 101 | 91 | 96 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE was reported for each arm.
| Participants | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Number of Participants Discontinuing Study Intervention Due to an AE | 6 | 4 | 7 |
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. DOR is defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis will be censored at the date of their last tumor assessment. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions is also considered PD. DOR assessments will be based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experience a confirmed CR or PR will be presented.
| Months | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR | NA (3.6 to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over Up to approximately 38 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib + Bevacizumab | 49/111 (44.1%) | 16/111 (14.4%) | 94/111 (84.7%) |
| Olaparib | 51/115 (44.3%) | 13/113 (11.5%) | 74/113 (65.5%) |
| Bevacizumab + Chemotherapy | 52/109 (47.7%) | 14/108 (13%) | 86/108 (79.6%) |
| Event | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/111 | 0/113 | 2/108 |
| Rectal haemorrhageGastrointestinal disorders | 0/111 | 2/113 | 0/108 |
| Acute coronary syndromeCardiac disorders | 0/111 | 0/113 | 1/108 |
| Atrial fibrillationCardiac disorders | 0/111 | 0/113 | 1/108 |
| Myocardial infarctionCardiac disorders | 0/111 | 0/113 | 1/108 |
| DiarrhoeaGastrointestinal disorders | 0/111 | 0/113 | 1/108 |
| Duodenal stenosisGastrointestinal disorders | 0/111 | 0/113 | 1/108 |
| EnteritisGastrointestinal disorders | 0/111 | 0/113 | 1/108 |
| Intestinal obstructionGastrointestinal disorders | 1/111 | 1/113 | 1/108 |
| Large intestinal obstructionGastrointestinal disorders | 0/111 | 0/113 | 1/108 |
| Event | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 32/111 | 21/113 | 8/108 |
| NauseaGastrointestinal disorders | 31/111 | 23/113 | 24/108 |
| Abdominal painGastrointestinal disorders | 19/111 | 8/113 | 13/108 |
| Decreased appetiteMetabolism and nutrition disorders | 15/111 | 18/113 | 12/108 |
| ConstipationGastrointestinal disorders | 16/111 | 11/113 | 14/108 |
| AstheniaGeneral disorders | 16/111 | 8/113 | 11/108 |
| DiarrhoeaGastrointestinal disorders | 11/111 | 9/113 | 15/108 |
| FatigueGeneral disorders | 14/111 | 15/113 | 10/108 |
| VomitingGastrointestinal disorders | 13/111 | 7/113 | 11/108 |
| StomatitisGastrointestinal disorders | 8/111 | 4/113 | 11/108 |
| Age, Continuous(Years) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| Mean | 59.5 ± 12.8 | 61.1 ± 10.7 | 63.2 ± 11.3 | 61.3 ± 11.7 |
| Sex: Female, Male(Participants) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| Female | 50 | 49 | 44 | 143 |
| Male | 61 | 66 | 65 | 192 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 16 | 10 | 44 |
| Not Hispanic or Latino | 88 | 93 | 94 | 275 |
| Unknown or Not Reported | 5 | 6 | 5 | 16 |
| Race (NIH/OMB)(Participants) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 10 | 5 | 4 | 19 |
| Asian | 25 | 40 | 30 | 95 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 71 | 64 | 66 | 201 |
| More than one race | 2 | 3 | 4 | 9 |
| Unknown or Not Reported | 3 | 3 | 4 | 10 |
| Response to Prior Induction(Participants) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| CR/PR | 49 | 48 | 47 | 144 |
| SD | 62 | 67 | 62 | 191 |
| Number of Induction Cycles(Participants) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| 6-8 cycles for FOLFOX + bevacizumab or 4-6 cycles for CAPOX + bevacizumab | 53 | 57 | 53 | 163 |
| >8 cycles for FOLFOX + bevacizumab or >6 cycles for CAPOX + bevacizumab | 58 | 58 | 56 | 172 |
| Mutation Status(Participants) | Olaparib + Bevacizumab | Olaparib | Bevacizumab + Chemotherapy | Total |
|---|---|---|---|---|
| BRAF and RAS all wild type | 32 | 33 | 29 | 94 |
| BRAF or RAS Mutation | 79 | 82 | 80 | 241 |
Showing the first 100 of 129 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2020 to primary completion in Mar 2023, 31 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 31 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olaparib · Bevacizumab